Log In
BCIQ
Print this Print this
 

HyQvia, Ig infusion 10%

Also known as: formerly HyQ

  Manage Alerts
Collapse Summary General Information
Company Baxalta Inc.
DescriptionSubcutaneous formulation of IV Gammagard, an IgG antibodies plasma-based therapy, and rHuPH20, a recombinant human PH20 hyaluronidase enzyme
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationImmunodeficiency
Indication DetailsTreat primary and secondary immunodeficiencies in patients ages 0-18; Treat primary immunodeficiency disorder (PID); Treat primary immunodeficiency disorders and myeloma or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections
Regulatory Designation U.S. - Standard Review (Treat primary immunodeficiency disorder (PID))
PartnerHalozyme Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$32,000.0M

$12,639.9M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/11/2016

$32,000.0M

$12,639.9M

0

Get a free BioCentury trial today